Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Nirmatrelvir/ritonavir is approved for the treatment of adults and pediatric patients with mild to moderate COVID-19, but information on adverse events associated with its use is limited. We aim to evaluate adverse events with potential risk for nirmatrelvir/ritonavir using the FDA Adverse Event Rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng, Zhang, Qing-Song, Liu, Xin-Ling, Wang, Hui-Ling, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786063/
https://www.ncbi.nlm.nih.gov/pubmed/36558906
http://dx.doi.org/10.3390/ph15121455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786063/
https://www.ncbi.nlm.nih.gov/pubmed/36558906
http://dx.doi.org/10.3390/ph15121455

Ejemplares similares